logo-loader
viewCytoDyn

Full interview: CytoDyn reveals adjustment to its HIV monotherapy treatment in 'major' announcement

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive that the firm’s Senior Science Advisor Dr. Jonah Sacha, who leads the development of leronlimab (PRO 140) as a potential therapeutic for HIV Pre-Exposure Prophylaxis (PrEP) and HIV, has 'tweaked' the product in-vitro to produce a therapy that would be injected only once per month.

Dr Pourhassan says the move comes with the biotech competing against the big pharma majors like Gilead Sciences and ViiV Healthcare, which have each revealed progression in their own therapies to treat HIV.

Quick facts: CytoDyn

Price: 0.337 USD

OTCMKTS:CYDY
Market: OTCMKTS
Market Cap: $130.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn receives IRB approval to treat triple-negative...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the Vancouver, Washington-based biotech has received approval from the Institutional Review Board for its drug leronlimab to be given to patients with triple-negative breast cancer (TNBC) under an expanded access...

1 day, 5 hours ago

2 min read